All Stories

  1. The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations
  2. Waxy‐ or Putty‐Like Materials as a Novel Drug Preparation for Synthetic Cannabinoid Receptor Agonists: Detection in Prisons and In Vitro Cannabinoid Receptor Activity
  3. Cardiorespiratory effects of gamma-hydroxybutyric acid (GHB) during isoflurane anaesthesia in pigs
  4. Review on activity-based detection of doping substances and growth promotors in biological matrices: do bioassays deserve a place in control programs?
  5. Nitazene test strips: a laboratory evaluation
  6. Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure
  7. Self-Sampling by Adolescents at Home: Assessment of the Feasibility to Successfully Collect Blood Microsamples by Inexperienced Individuals
  8. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials
  9. In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids
  10. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs
  11. Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited
  12. Is the stability of folates in dried blood microsamples sufficient to perform home-sampling studies?
  13. Untargeted Detection of HIF Stabilizers in Doping Samples: Activity-Based Screening with a Stable In Vitro Bioassay
  14. In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs
  15. Assay-Dependent Inverse Agonism at the A3 Adenosine Receptor: When Neutral Is Not Neutral
  16. In vitro cannabinoid receptor activity, metabolism, and detection in seized samples of CH‐PIATA, a new indole‐3‐acetamide synthetic cannabinoid
  17. In vitro μ‐opioid receptor activation potential of U10 and β‐U10, positional isomers of the synthetic opioid naphthyl U‐47700
  18. Structure–Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists
  19. Increasing Confidence in a Phosphatidylethanol 16:0/18:1 Cutoff at 20 ng/mL to Support Abstinence or Minor Intake of Alcohol
  20. Remote HbA1c testing via microsampling: fit for purpose?
  21. Detection, chemical analysis, and pharmacological characterization of dipyanone and other new synthetic opioids related to prescription drugs
  22. Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
  23. Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor
  24. Liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants and creatinine from a single dried blood spot using the Capitainer® qDBS device
  25. Comparison of near-infrared and UV–vis-based non-contact hematocrit prediction of dried blood spots from patients on immunosuppressants
  26. Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients
  27. DRIED BLOOD MICROSAMPLING-ASSISTED THERAPEUTIC DRUG MONITORING OF IMMUNOSUPPRESSANTS: AN OVERVIEW
  28. Application OF NON-CONTACT hematocrit prediction technologies to overcome hematocrit effects on immunosuppressant quantification from dried blood spots
  29. Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists
  30. Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites
  31. Development of an Indole-Amide-Based Photoswitchable Cannabinoid Receptor Subtype 1 (CB1R) “Cis-On” Agonist
  32. Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 Consensus of Basel)
  33. In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress
  34. Frontispiece: Enlightening the “Spirit Molecule”: Photomodulation of the 5‐HT 2A Receptor by a Light‐Controllable N , N ‐Dimethyltryptamine Derivative
  35. Frontispiz: Die Erhellung des “Bewusstseinsmoleküls”: Photomodulation des 5‐HT 2A Rezeptors durch ein licht‐steuerbares N,N‐Dimethyltryptamin‐Derivat
  36. Analytical performance of eight enzymatic assays for ethanol in serum evaluated by data from the Belgian external quality assessment scheme
  37. Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice
  38. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists
  39. A new cannabinoid receptor 1 selective agonist evading the 2021 ‘China ban’: ADB‐FUBIATA
  40. Die Erhellung des “Bewusstseinsmoleküls”: Photomodulation des 5‐HT 2A Rezeptors durch ein licht‐steuerbares N,N‐Dimethyltryptamin‐Derivat
  41. Enlightening the “Spirit Molecule”: Photomodulation of the 5‐HT 2A Receptor by a Light‐Controllable N , N ‐Dimethyltryptamine Derivative
  42. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole ‘nitazene’ synthetic opioid
  43. First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass
  44. Machine Learning to Assist in Large-Scale, Activity-Based Synthetic Cannabinoid Receptor Agonist Screening of Serum Samples
  45. The P2Y2 Receptor C-Terminal Tail Modulates but Is Dispensable for β-Arrestin Recruitment
  46. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
  47. Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238
  48. Monitoring the use of alcohol—A critical overview of the state‐of‐the‐art biomarkers
  49. Current evolutions, applications, and challenges of phosphatidylethanol analysis for clinical and forensic purposes
  50. Cov2MS: an automated matrix-independent assay for mass spectrometric detection and measurement of SARS-CoV-2 nucleocapsid protein in infectious patients
  51. A novel panel of yeast assays for the assessment of thiamin and its biosynthetic intermediates in plant tissues
  52. Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays
  53. Set‐up of a population‐based model to verify alcohol abstinence via monitoring of the direct alcohol marker phosphatidylethanol 16:0/18:1
  54. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5‐HT 2A R
  55. Structure–activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA
  56. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors
  57. In-depth evaluation of automated non-contact reflectance-based hematocrit prediction of dried blood spots
  58. Near-infrared-based hematocrit prediction of dried blood spots: An in-depth evaluation
  59. Receptor density influences ligand-induced dopamine D2L receptor homodimerization
  60. A3 adenosine receptor agonists containing dopamine Moieties for enhanced interspecies affinity
  61. Determination of paracetamol and its metabolites via LC-MS/MS in dried blood volumetric absorptive microsamples: A tool for pharmacokinetic studies
  62. Are the N ‐demethylated metabolites of U‐47700 more active than their parent compound? In vitro μ‐opioid receptor activation of N ‐desmethyl‐U‐47700 and N , N ...
  63. Sensing an Oxygen Sensor: Development and Application of Activity-Based Assays Directly Monitoring HIF Heterodimerization
  64. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?
  65. Fully Automated Dried Blood Spot Extraction coupled to Liquid Chromatography-tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants
  66. The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament
  67. Porphyrins produced by acneic Cutibacterium acnes strains activate the inflammasome by inducing K+ leakage
  68. Alternative Sampling Strategies in Therapeutic Drug Monitoring: Microsampling Growing Toward Maturity
  69. Volumetric absorptive microsampling (VAMS) as a reliable tool to assess thiamine status in dried blood microsamples: a comparative study
  70. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA using a combination of binding and different CB1 receptor activation assays. Part...
  71. Volumetric Absorptive Microsampling as an Alternative Tool for Biomonitoring of Multi-Mycotoxin Exposure in Resource-Limited Areas
  72. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA using a combination of binding and different CB 1 recepto...
  73. Metabolic engineering provides insight into the regulation of thiamin biosynthesis in plants
  74. Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method
  75. Synthesis and Functional Characterization of 2-(2,5-Dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine (25H-NBF) Positional Isomers
  76. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB‐4en‐PICA, MDMB‐4en‐PINACA, ADB‐4en‐PINACA, and MMB‐4CN‐BUTINACA using a combination of binding and different CB 1 recepto...
  77. Obituary Peter Blanckaert
  78. Phenethyl-4-ANPP: A Marginally Active Byproduct Suggesting a Switch in Illicit Fentanyl Synthesis Routes
  79. Simultaneous readout of multiple FRET pairs using photochromism
  80. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids
  81. Synthesis, chemical characterization, and µ-opioid receptor activity assessment  of the emerging group of ‘nitazene’ 2-benzylbenzimidazole synthetic  opioids             
  82. The Balance of MU-Opioid, Dopamine D2 and Adenosine A2A Heteroreceptor Complexes in the Ventral Striatal-Pallidal GABA Antireward Neurons May Have a Significant Role in Morphine and Cocaine Use Disorders
  83. An optimized LC-MS/MS method as a pivotal tool to steer thiamine biofortification strategies in rice
  84. Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking
  85. Metabolic engineering of rice endosperm towards higher vitamin B1 accumulation
  86. Quantitation of phosphatidylethanol in dried blood after volumetric absorptive microsampling
  87. Alternative Sampling Devices to Collect Dried Blood Microsamples
  88. Patient-Centric Assessment of Thiamine Status in Dried Blood Volumetric Absorptive Microsamples Using LC–MS/MS Analysis
  89. Simultaneous readout of multiple FRET pairs using photochromism
  90. Shape matters: The application of activity‐based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug‐infused papers seized in prisons
  91. Understanding the pharmacokinetics of synthetic cathinones: Evaluation of the blood–brain barrier permeability of 13 related compounds in rats
  92. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays
  93. Recent developments in electrochemical detection of illicit drugs in diverse matrices
  94. Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA,...
  95. Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse
  96. Cov-MS: a community-based template assay for clinical MS-based protein detection in SARS-CoV-2 patients
  97. Self-sampling at home using volumetric absorptive microsampling: coupling analytical evaluation to volunteers’ perception in the context of a large scale study
  98. The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent‐4en and but‐3en analogues including MDMB‐4en‐PINACA
  99. Hematocrit prediction in volumetric absorptive microsamples
  100. A novel nanobody-based bio-assay using functional complementation of a split nanoluciferase to monitor Mu- opioid receptor activation
  101. Dried blood microsample-assisted determination of vitamins: recent developments and challenges
  102. Correction to: In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor
  103. First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
  104. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances
  105. In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor
  106. In vitro activity profiling of Cumyl‐PEGACLONE variants at the CB 1 receptor: Fluorination versus isomer exploration
  107. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology
  108. Report on a new opioid NPS: chemical and in vitro functional characterization of a structural isomer of the MT-45 derivative diphenpipenol
  109. Dried Blood Microsampling-Based Therapeutic Drug Monitoring of Antiepileptic Drugs in Children With Nodding Syndrome and Epilepsy in Uganda and the Democratic Republic of the Congo
  110. Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine
  111. Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping
  112. Striatal Dopamine D2-Muscarinic Acetylcholine M1 Receptor–Receptor Interaction in a Model of Movement Disorders
  113. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform
  114. Assessment of biased agonism at the A3 adenosine receptor using β-arrestin and miniGαi recruitment assays
  115. The First Comprehensive LC–MS/MS Method Allowing Dissection of the Thiamine Pathway in Plants
  116. Dried blood microsamples: suitable as an alternative matrix for the quantification of paracetamol-protein adducts?
  117. Development, validation and application of an inductively coupled plasma – mass spectrometry method to determine cobalt in metal-on-metal prosthesis patients using volumetric absorptive microsampling
  118. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene
  119. Comment on HbA 1c determination from HemaSpot blood collection devices: comparison of home‐prepared dried blood spots with standard venous blood analysis
  120. Kainic acid-induced status epilepticus decreases mGlu5 receptor and phase-specifically downregulates Homer1b/c expression
  121. Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screeni...
  122. Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds
  123. Evaluation of the Performance and Hematocrit Independence of the HemaPEN as a Volumetric Dried Blood Spot Collection Device
  124. EASL Clinical Practice Guideline: Occupational liver diseases
  125. Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests
  126. Fully automated therapeutic drug monitoring of anti-epileptic drugs making use of dried blood spots
  127. Editorial: Advances in Analytical Methods for Drugs of Abuse Testing
  128. Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor
  129. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists
  130. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot–Based Methods for Therapeutic Drug Monitoring
  131. Comprehensive investigation on synthetic cannabinoids: Metabolic behavior and potency testing, using 5F‐APP‐PICA and AMB‐FUBINACA as model compounds
  132. Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact
  133. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐ tert ‐leucine
  134. Luminescence- and Fluorescence-Based Complementation Assays to Screen for GPCR Oligomerization: Current State of the Art
  135. Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples
  136. Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimer’s disease
  137. Distinct Dopamine D2 Receptor Antagonists Differentially Impact D2 Receptor Oligomerization
  138. Activity-based reporter assays for the screening of abused substances in biological matrices
  139. Clinical determination of folates: recent analytical strategies and challenges
  140. The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy
  141. Is the hematocrit still an issue in quantitative dried blood spot analysis?
  142. Validation of Activity-Based Screening for Synthetic Cannabinoid Receptor Agonists in a Large Set of Serum Samples
  143. Wet absorptive microsampling at home for HbA1c monitoring in diabetic children
  144. Application of an activity‐based receptor bioassay to investigate the in vitro activity of selected indole‐ and indazole‐3‐carboxamide‐based synthetic cannabinoids at CB1 and CB2 receptors
  145. Quantification of Cocaine and Cocaine Metabolites in Dried Blood Spots from a Controlled Administration Study Using LC-MS/MS
  146. Volumetric absorptive microsampling as an alternative sampling strategy for the determination of paracetamol in blood and cerebrospinal fluid
  147. Determination of Cocaine and Metabolites in Dried Blood Spots by LC-MS/MS
  148. Probing Structure-Activity Relationship in β-Arrestin2 Recruitment of Diversely Substituted Adenosine Derivatives
  149. Evaluation of the Capitainer-B Microfluidic Device as a New Hematocrit-Independent Alternative for Dried Blood Spot Collection
  150. Synthesis toward Bivalent Ligands for the Dopamine D2 and Metabotropic Glutamate 5 Receptors
  151. Activity-Based Concept to Screen Biological Matrices for Opiates and (Synthetic) Opioids
  152. Activity-Based Detection and Bioanalytical Confirmation of a Fatal Carfentanil Intoxication
  153. Design, Synthesis, and Biological Evaluation of Bivalent Ligands Targeting Dopamine D2 -Like Receptors and the μ-Opioid Receptor
  154. Activity-Based Detection of Cannabinoids in Serum and Plasma Samples
  155. Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review
  156. Correction to: Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs
  157. Molecular dissection of the human A 3 adenosine receptor coupling with β-arrestin2
  158. Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs
  159. Correction for the Hematocrit Bias in Dried Blood Spot Analysis Using a Nondestructive, Single-Wavelength Reflectance-Based Hematocrit Prediction Method
  160. Folate Biofortification of Potato by Tuber-Specific Expression of Four Folate Biosynthesis Genes
  161. Assessing GPCR Dimerization in Living Cells: Comparison of the NanoBiT Assay with Related Bioluminescence- and Fluorescence-Based Approaches
  162. Dried blood spots in therapeutic drug monitoring and toxicology
  163. Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants
  164. Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System
  165. Alternative sampling strategies for the assessment of biomarkers of exposure
  166. The (non)sense of routinely analysing beta-hydroxybutyric acid in forensic toxicology casework
  167. Folates in Plants: Research Advances and Progress in Crop Biofortification
  168. Biomarkers in patients admitted to the emergency department after exposure to acrylonitrile in a major railway incident involving bulk chemical material
  169. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015
  170. Volumetric absorptive microsampling at home as an alternative tool for the monitoring of HbA1c in diabetes patients
  171. Dried blood spot analysis of gabapentin as a valid alternative for serum: a bridging study
  172. Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay
  173. Opening the toolbox of alternative sampling strategies in clinical routine: A key-role for (LC-)MS/MS
  174. Alternative sampling strategies for the assessment of alcohol intake of living persons
  175. Microwave-assisted on-spot derivatization for gas chromatography–mass spectrometry based determination of polar low molecular weight compounds in dried blood spots
  176. Quantification of EtG in hair, EtG and EtS in urine and PEth species in capillary dried blood spots to assess the alcohol consumption in driver’s licence regranting cases
  177. Short-term health effects in the general population following a major train accident with acrylonitrile in Belgium
  178. A Novel, Nondestructive, Dried Blood Spot-Based Hematocrit Prediction Method Using Noncontact Diffuse Reflectance Spectroscopy
  179. Degradation and interconversion of plant pteridines during sample preparation and ultra-high performance liquid chromatography–tandem mass spectrometry
  180. Alternative Sampling Strategies for Therapeutic Drug Monitoring
  181. Consumer Acceptance and Willingness-to-Pay for Genetically Modified Foods with Enhanced Vitamin Levels
  182. Disulfiram inhibition of cyanide formation after acetonitrile poisoning
  183. Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol withdrawal and control volunteers
  184. Determination of Five Folate Monoglutamates in Rodent Diets
  185. An optimized and validated SPE-LC–MS/MS method for the determination of caffeine and paraxanthine in hair
  186. Improving folate (vitamin B9) stability in biofortified rice through metabolic engineering
  187. DBS and beyond
  188. Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept
  189. DBS and beyond
  190. Alternative Sampling Strategies for Cytochrome P450 Phenotyping
  191. A validated ultra-high-performance liquid chromatography–tandem mass spectrometry method for the selective analysis of free and total folate in plasma and red blood cells
  192. Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study
  193. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples
  194. Folates from metabolically engineered rice: A long-term study in rats
  195. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
  196. Do capillary dried blood spot concentrations of gamma-hydroxybutyric acid mirror those in venous blood? A comparative study
  197. Acrylonitrile exposure assessment in the emergency responders of a major train accident in Belgium: A human biomonitoring study
  198. Acrylonitrile exposure in the general population following a major train accident in Belgium: A human biomonitoring study
  199. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma
  200. Potassium-based algorithm allows correction for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood spots
  201. Spot them in the spot: analysis of abused substances using dried blood spots
  202. Antipsychotics in dried blood spots
  203. Why Dried Blood Spots Are an Ideal Tool for CYP1A2 Phenotyping
  204. Current strategies for coping with the hematocrit problem in dried blood spot analysis
  205. Derivatization Techniques in Dried Blood Spot Analysis
  206. Folate Profiling in Potato (Solanum tuberosum) Tubers by Ultrahigh-Performance Liquid Chromatography–Tandem Mass Spectrometry
  207. Screening and confirmation methods for GHB determination in biological fluids
  208. Letter to the Editor
  209. Enhancing pterin and para-aminobenzoate content is not sufficient to successfully biofortify potato tubers and Arabidopsis thaliana plants with folate
  210. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions
  211. Rice folate enhancement through metabolic engineering has an impact on rice seed metabolism, but does not affect the expression of the endogenous folate biosynthesis genes
  212. Determination of gamma-hydroxybutyric acid in biofluids using a one-step procedure with “in-vial” derivatization and headspace-trap gas chromatography–mass spectrometry
  213. Feasibility of Following up Gamma-Hydroxybutyric Acid Concentrations in Sodium Oxybate (Xyrem®)-Treated Narcoleptic Patients Using Dried Blood Spot Sampling at Home
  214. Biofortified Rice to Fight Folate Deficiency
  215. Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer
  216. Fatality following a suicidal overdose with varenicline
  217. Isolation and characterisation of an antifolate insensitive (afi1) mutant ofArabidopsis thaliana
  218. Inhibition of p-Aminobenzoate and Folate Syntheses in Plants and Apicomplexan Parasites by Natural Product Rubreserine
  219. Interaction of α-Catulin with Dystrobrevin Contributes to Integrity of Dystrophin Complex in Muscle
  220. Dried blood spots in toxicology: from the cradle to the grave?
  221. A folate independent role for cytosolic HPPK/DHPS upon stress in Arabidopsis thaliana
  222. Dried blood spot punches for confirmation of suspected γ-hydroxybutyric acid intoxications: validation of an optimized GC–MS procedure
  223. Quantitative liquid chromatographic analysis of anthracyclines in biological fluids
  224. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells
  225. Determination of gamma-hydroxybutyric acid in dried blood spots using a simple GC-MS method with direct “on spot” derivatization
  226. Mice in Ecstasy: Advanced Animal Models in the Study of MDMA
  227. Post-Mortem (Re)Distribution of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): Human and Animal Data
  228. A field study on 8 pharmaceuticals and 1 pesticide in Belgium: Removal rates in waste water treatment plants and occurrence in surface water
  229. P-cadherin in adhesion and invasion: Opposite roles in colon and bladder carcinoma
  230. The Transcriptional Repressor Kaiso Localizes at the Mitotic Spindle and Is a Constituent of the Pericentriolar Material
  231. Ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) for the sensitive determination of folates in rice
  232. Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva
  233. Optimisation and validation of a liquid chromatography–tandem mass spectrometry method for folates in rice
  234. Optimization of a liquid chromatographic separation for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites
  235. E-Cadherin Regulates Human Nanos1, which Interacts with p120ctn and Induces Tumor Cell Migration and Invasion
  236. Human Immunodeficiency Virus Nef Induces Rapid Internalization of the T-Cell Coreceptor CD8αβ
  237. P-Cadherin Promotes Cell-Cell Adhesion and Counteracts Invasion in Human Melanoma
  238. Human Immunodeficiency Virus Nef Induces Rapid Internalization of the T-Cell Coreceptor CD8αβ
  239. The Transcription Factor Snail Induces Tumor Cell Invasion through Modulation of the Epithelial Cell Differentiation Program
  240. Roles for neuregulins in human cancer
  241. Bowes melanoma cells secrete heregulin, which can promote aggregation and counteract invasion of human mammary cancer cells
  242. P-Cadherin Is Up-Regulated by the Antiestrogen ICI 182,780 and Promotes Invasion of Human Breast Cancer Cells
  243. Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition
  244. Signaling but not trafficking function of HIV-1 protein Nef is essential for Nef-induced defects in human intrathymic T-cell development
  245. The Heregulin/Human Epidermal Growth Factor Receptor as a New Growth Factor System in Melanoma with Multiple Ways of Deregulation
  246. Synthesis, characterization and in vitro anti-invasive activity screening of polyphenolic and heterocyclic compounds
  247. Plasmin Produces an E-Cadherin Fragment That Stimulates Cancer Cell Invasion
  248. The Citrus Methoxyflavone Tangeretin Affects Human Cell-Cell Interactions
  249. 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cells